On June 5, 2022 Creatv Bio, Division of Creatv MicroTech, Inc., reported the release of an abstract featuring the results of its LifeTracDx blood test for predicting response of metastatic breast cancer (mBC) to new lines of therapy following a single cycle of therapy induction (Press release, Creatv Bio, JUN 5, 2022, View Source [SID1234615586]). The results will be presented at the 2022 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) ("ASCO") Annual Meeting June 3-7, 2022, one of the most influential oncology events in the world for presenting new cutting-edge advances in cancer science that will shape the future of cancer treatment.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Creatv Bio’s poster presents data showing that analysis of circulating stromal cells and circulating tumor cells from the blood of mBC patients undergoing therapy can predict tumor responsiveness to a new line of therapy within a single cycle of treatment, regardless of disease subtype or drug classification, including the cancer vaccine, Bria-IMTTM, developed by BriaCell Therapeutics Corp. (NASDAQ: BCTX) (TSX: BCT).
Session Title: Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Session Date and Time: June 5th, 2022, 8:00AM-11:00AM
Poster Title: Tracking Changes in Circulating Stromal Cells and Circulating Tumor Cells Predicts Responsiveness of New Line Induction in Metastatic Breast Cancer after 1 Cycle of Therapy
Poster Location: Poster number: 48; Abstract number: 3056
Daniel L. Adams, Creatv Bio Director of Clinical R&D, stated, "We are excited for the opportunity to present these results to the leaders in oncology and hope this study leads to larger interventional trials that one day will help all cancer patients. LifeTracDx ‘s ability to rapidly identify MBC patients responding to a new therapeutic regimen after only one cycle of treatment could eventually be used to rapidly assess and alter patient’s therapy in real time, leading to improved patient outcomes."
"We are looking forward to continuing our work with the experts at Creatv Bio as we advance the clinical development of our novel cellular immunotherapy for advanced breast cancer," stated Dr. Giuseppe Del Priore, Chief Medical Officer of BriaCell. "We are hopeful that the technology will allow us to better identify breast cancer patients most likely to benefit from novel therapies."